Management of hematologic malignancies in the elderly: 15-year experience at the Aviano Cancer Center, Italy

Critical Reviews in Oncology/Hematology

Volumn 39, Issue 3, 2001, Pages 289-305

  Zagonel, Vittorina ^a,b   Monfardini, Silvio ^a   Tirelli, Umberto ^a   Carbone, Antonino ^a   Pinto, Antonio ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Acute myeloblastic leukemia; CHOP; Decitabine; Elderly patients; Idarubicin; Multiple myeloma; Myelodysplastic syndromes; Non Hodgkin's lymphoma; VMP

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; VINCRISTINE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; BURKITT LYMPHOMA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; EVALUATION; GERIATRICS; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; ITALY; MEDICINE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PROGNOSIS; REVIEW;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DISEASE MANAGEMENT; FEMALE; GERIATRIC ASSESSMENT; HEMATOLOGIC NEOPLASMS; HUMANS; ITALY; MALE;

EID: 0034908785     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00126-8     Document Type: Review

References (53)

1. Needed: clinical trials for older patients
2. Complications of cytotoxic therapy
3. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma. Results of a tree structured survival analysis
4. Strategies to prevent chemotherapy related toxicity in the older person
5. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients
6. Non-Hodgkin's lymphoma in the elderly: a retrospective clinico-pathologic study of 56 patients
7. Non-Hodgkin's lymphomas in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Group Study
8. Management of non-Hodgkin's lymphomas in elderly patients: conclusions of the Second Intercity Meeting, 1987
9. Cancer in the elderly: why so badly treated
10. Cancer treatment and old people
11. Commission of the European Communities 'Europe against cancer' programme. European school of oncology advisory report Cancer treatment in the elderly
12. Acute myeloid leukemia in the elderly
13. Acute myeloblastic leukemia in the elderly: biology, prognostic factors and treatment
14. Acute myeloid leukemia in the elderly: biology and treatment
15. 5-aza-2′-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends
16. 5-aza-2′-deoxycytidine (decitabine): induces trilineage response in unfavourable myelodysplastic syndromes
17. Pilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients. Preliminary results
18. In vitro and in vivo effects of 5-aza-2′-deoxycyti dine (decitabine) on clonogenic cells from acute myeloid leukemia patients
19. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy
20. Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine
21. 5-aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemia
22. Fourth International Workshop on Chromosome in Leukemia: clinical significance of chromosomal abnormalities in acute non-lymphoblastic leukemia
23. Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
24. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
25. Non-Hodgkin's lymphoma in the elderly. I. Pathologic features at presentation
26. Pathological and immunophenotypic features of adult non-Hodgkin's lymphoma by age group
27. Combination chemotherapy specifically devised for elderly patients with unfavorable non-Hodgkin's lymphoma
28. A prospective study of a new combination of chemotherapy regimen in patients older than 70 years with unfavourable non-Hodgkin's lymphoma
29. Mitoxantrone in combination with etoposide and prednimustine (VMP) in patients older than 70 years with unfavourable non-Hodgkin's lymphoma: a prospective study in 52 patients
30. CHOP is the standard regimen in patients of 70 years of age of more with intermediate and high grade non-Hodgkin's lymphoma: results of a randomized study of the EORTC Lymphoma Cooperative Study Group
31. Treatment of lymphoma in the elderly: an update
32. VP16, mitoxantrone and prednimustine (VMP) with or without G-CSF in patients pts) with non-Hodgkin's lymphoma (NHL) older than 70 years (yrs)
33. Cost-benefit of granulocyte colonystimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy
34. Combined modality therapy for adult with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types)
35. Pharmacokinetics and safety of Idarubicin continuous infusion (civ) in elderly patients (ep) with aggressive lymphomas (AL)
36. Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the treated since 1945
37. Multiple myeloma. In: Guidelines for the management of cancer in the elderly
38. High-dose therapy for refractary multiple myeloma: improved prognosis with better supportive care and double transplants
39. Treatment of multiple myeloma and acute myelogenous leukemia in the elderly: an update
40. Validation of multidimensional evaluation scale for use in elderly cancer patients
41. The Comprehensive Geriatric Assessment in elderly cancer patients. Preliminary results from the Italian Group of Geriatric Oncology-GIOGer
42. The impact of cancer on the physical function of the elderly and their utilization of health care
43. Fludarabine, cytarabine and granulocytecolony stimulating factor for the treatment of high risk myelodysplastic syndromes